The National Heart, Lung, and Blood Institute seeks adults with severe aplastic anemia (SAA) for a research study determining viability and safety of early initiation of oral therapy with cyclosporine and eltrombopag in patients with SAA. All patients will receive standard treatment with cyclosporine, eltrombopag and Horse Anti-thymocyte-Globulin (h-ATG) unless there is complete count recovery with oral therapy. Compensation will be provided.
For more information, contact the Office of Patient Recruitment at 1-866-444-2214 (TTY user dial 7-1-1) of visit https://go.nih.gov/KnlRIpY. Refer to study 20-H-0033.